SILO PHARMA, INC. Net Income (Loss) Allocated to General Partners
SILO PHARMA, INC. (SILO) reported Net Income (Loss) Allocated to General Partners of $3.90 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NetIncomeLossAllocatedToGeneralPartners · last filed 2022-03-28
- SILO PHARMA, INC. net income (loss) allocated to general partners for fiscal 2021 was $3.90M.
- SILO PHARMA, INC. net income (loss) allocated to general partners for fiscal 2020 was -$3.04M.
| Period end | Net Income (Loss) Allocated to General Partners 12 month |
|---|---|
| 2021-12-31 | $3.90M 10-K · filed 2022-03-28 |
| 2020-12-31 | -$3.04M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |